Evidence map›Paper›PMID 28092670›Full record

ArticleOncogene2017

Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality.

B W C Tse, M Volpert, E Ratther, N Stylianou, M Nouri, K McGowan, M L Lehman, S J McPherson, M Roshan-Moniri, M S Butler and 24 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 2 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 2 syntheses or guidelines pooled it, 92 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Myeloid checkpoints for cancer immunotherapy.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors at 12 institutions in 3 countries.

B W C TseAustralian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, School of Biomedical Science, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute, Brisbane, Queensland, Australia.
M VolpertAustralian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, School of Biomedical Science, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute, Brisbane, Queensland, Australia.
E RattherAustralian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, School of Biomedical Science, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute, Brisbane, Queensland, Australia.
N StylianouAustralian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, School of Biomedical Science, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute, Brisbane, Queensland, Australia.
M NouriVancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada.
K McGowanAustralian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, School of Biomedical Science, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute, Brisbane, Queensland, Australia.
M L LehmanAustralian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, School of Biomedical Science, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute, Brisbane, Queensland, Australia.
S J McPhersonAustralian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, School of Biomedical Science, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute, Brisbane, Queensland, Australia.
M Roshan-MoniriVancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada.
M S ButlerVancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada.
J CaradecVancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada.
C Y Gregory-EvansDepartment of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
J McGovernTissue Repair and Regeneration Program, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland, Australia.
R DasDame Roma Mitchell Cancer Research Laboratories and Freemason's Foundation Centre for Men's Health, Discipline of Medicine, University of Adelaide, Adelaide, South Australia, Australia.
M TakharGenomeDX Biosciences, Vancouver, British Columbia, Canada.
N ErhoGenomeDX Biosciences, Vancouver, British Columbia, Canada.
M AlshalafaGenomeDX Biosciences, Vancouver, British Columbia, Canada.
E DavicioniGenomeDX Biosciences, Vancouver, British Columbia, Canada.
E M SchaefferDepartment of Urology, Northwestern University, Chicago, IL, USA.
R B JenkinsDepartment of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, MN, USA.
A E RossDepartment of Urology, Brady Urological Institute, Johns Hopkins University, Baltimore, MD, USA.
R J KarnesDepartment of Urology, Mayo Clinic, Rochester, MN, USA.
R B DenSidney Kimmel Medical College, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
L FazliVancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada.
P A GregoryCentre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, South Australia, Australia.
M E GleaveVancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada.
E D WilliamsAustralian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, School of Biomedical Science, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute, Brisbane, Queensland, Australia.
P S RennieVancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada.
R ButtyanVancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada.
J H GunterAustralian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, School of Biomedical Science, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute, Brisbane, Queensland, Australia.
L A SelthDame Roma Mitchell Cancer Research Laboratories and Freemason's Foundation Centre for Men's Health, Discipline of Medicine, University of Adelaide, Adelaide, South Australia, Australia.
P J RussellAustralian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, School of Biomedical Science, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute, Brisbane, Queensland, Australia.
C C NelsonAustralian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, School of Biomedical Science, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute, Brisbane, Queensland, Australia.
B G HollierAustralian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, School of Biomedical Science, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute, Brisbane, Queensland, Australia.
University of British Columbia · CAQueensland University of Technology · AUGenome British Columbia · CAPrincess Alexandra Hospital · AUMayo Clinic in Arizona · USFreemasons Foundation Centre for Men's Health · AUJohns Hopkins University · USNorthwestern University · USThe University of Adelaide · AUThomas Jefferson University Hospital · USTranslational Research Institute · AUUniversity of South Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent evidence has implicated the transmembrane co-receptor neuropilin-1 (NRP1) in cancer progression. Primarily known as a regulator of neuronal guidance and angiogenesis, NRP1 is also expressed in multiple human malignancies, where it promotes tumor angiogenesis. However, non-angiogenic roles of NRP1 in tumor progression remain poorly characterized. In this study, we define NRP1 as an androgen-repressed gene whose expression is elevated during the adaptation of prostate tumors to androgen-targeted therapies (ATTs), and subsequent progression to metastatic castration-resistant prostate cancer (mCRPC). Using short hairpin RNA (shRNA)-mediated suppression of NRP1, we demonstrate that NRP1 regulates the mesenchymal phenotype of mCRPC cell models and the invasive and metastatic dissemination of tumor cells in vivo. In patients, immunohistochemical staining of tissue microarrays and mRNA expression analyses revealed a positive association between NRP1 expression and increasing Gleason grade, pathological T score, positive lymph node status and primary therapy failure. Furthermore, multivariate analysis of several large clinical prostate cancer (PCa) cohorts identified NRP1 expression at radical prostatectomy as an independent prognostic biomarker of biochemical recurrence after radiation therapy, metastasis and cancer-specific mortality. This study identifies NRP1 for the first time as a novel androgen-suppressed gene upregulated during the adaptive response of prostate tumors to ATTs and a prognostic biomarker of clinical metastasis and lethal PCa.

Indexed as

Up-RegulationAndrogen AntagonistsCell Line, TumorDisease ProgressionEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansMaleNeoplasm GradingNeoplasm MetastasisNeuropilin-1Prostatic NeoplasmsProstatic Neoplasms, Castration-ResistantSurvival AnalysisAndrogen AntagonistsNeuropilin-1

Identifiers

PMID28092670
PMCPMC5485179
OpenAlexW2577681251

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.